Awareness and Acceptance Regarding Covid-19 Vaccination and Determinants of Vaccine Uptake: A Cross-Sectional Analysis

Dr Alka Modi Asati^{1*}, Dr Richa Siddharth², Dr Yogesh Singh Kaurav³, Dr Sanjay Goyal⁴, Dr. Veena Sinha⁵, Shailendra Kumar Singh⁶, Vineet Kumar Tiwari⁷

Orcid Id: 0000-0003-3634-9784

Corresponding Author: Dr Alka Modi Asati

Abstract: Background: Despite extensive efforts by both the community and government, COVID-19 remains a persistent threat. Vaccination and adherence to COVID-appropriate behaviours are crucial in curbing the pandemic. This study aimed to assess awareness, acceptance, and determinants of COVID-19 vaccination. Materials and Methods: An analytical cross-sectional study involving 400 respondents after obtaining verbal consent, was conducted between February 5th and February 20th, 2022. Structured questionnaires collected data on sociodemographics, COVID-19 infection/vaccination status, vaccine awareness, motivation, and reasons for refusal. Results: Among 400 respondents, 62.7% were aged 18-40 years, and 67.8% were male. High awareness (96%) of vaccine protection against infection was observed, with 99.8% supporting compulsory vaccination. Most (94.7%) were vaccinated for self-protection, citing efficacy doubts and side effect concerns as primary reasons for refusal. Conclusion: The study highlights satisfactory awareness and positive attitudes toward COVID-19 vaccination. Enhanced awareness campaigns and addressing safety concerns can further boost vaccine acceptance. Accurate vaccine information is essential to promote adherence to government guidelines in combating vaccine-preventable diseases.

Keywords: COVID-19, Vaccination, Vaccine Acceptance, Awareness, COVID-19 Vaccine

Awareness and Acceptance Regarding COVID-19 Vaccination and Determinants of Vaccine Uptake: A Cross-Sectional Analysis

Introduction: Since 2020, India has grappled with the COVID-19 epidemic, with the first case recorded on January 30, 2020, in Kerala.¹ Despite two years of concerted efforts by both the community and the government, COVID-19 remains a persistent pandemic. The Indian government has implemented various measures to curb COVID-19 transmission, including lockdowns, closure of educational and office institutions,

awareness campaigns, and the distribution of free COVID-19 vaccines. Balancing health measures with economic stability underscores the need for a collective effort between the government and the community. COVID-appropriate behaviours such as mask-wearing, social distancing, and hand hygiene, alongside vaccination, represent effective strategies in combating the crisis.

Previous research and ongoing clinical trials underscore the importance of safe and effective COVID-19 vaccines in controlling the pandemic.² Vaccination campaigns have historically proven successful in combating infectious diseases, making vaccines among the most reliable and cost-effective public health interventions, saving millions of lives annually. Immunity against the virus can be acquired either through natural infection or vaccination.³

Amidst the global spread of the virus, vaccination emerges as a crucial tool in halting community transmission of COVID-19. In India, vaccines like Covishield and Covaxin have been authorized for use and distributed nationwide.⁴ As of May 30, 2022, India has reported over 53 crore COVID-19 cases and 63 lakh deaths globally, with approximately 43 crore cases and 5 lakh deaths occurring in India,⁵ including around 10 lakh cases and over 10 thousand deaths in Madhya Pradesh.⁶ Vaccination coverage stands at 60.6% globally, 64.3% in India, and 69.7% in Madhya Pradesh.⁷

Despite vaccine availability, inadequate information about vaccine types, efficacy, dosing recommendations, and prevalent vaccine hesitancy pose significant challenges to infection control efforts. This study aims to assess COVID-19 vaccination awareness and acceptance, alongside associated factors, among the general public.

Materials and Method: This analytical, cross-sectional study was conducted by the IDSP cell, Directorate of Health Services, Bhopal, Madhya Pradesh, from February 5 to February 20, 2022. A random sampling method was employed to determine the sample size. From a pool of 10,279 mobile numbers representing residents of all districts of Madhya Pradesh, obtained from the telecommunication department, 3000 participants were randomly selected to ensure representation from each district by convenient sampling. Only individuals willing to participate were included in the study, resulting in 400 responses. Confidentiality and anonymity were strictly maintained throughout the study. Ethical approval was taken from the institution board. AsThis investigation was done under the Integrated Disease Surveillance Project cell of Directorate of Health services for monitoring purpose of COVID-19 vaccination campaign and feedback. All investigators and corresponding author were affiliated with DHS.

Data Collection and Tool: Structured questionnaires were utilized to collect data for this study. Drawing upon existing literature, experts prepared and validated the questionnaire. Prior to data collection, participants were briefed on the study's objectives, purpose, and implications. The questionnaire was administered via telephone interviews using a Google form, facilitated by our counsellors. It covered

various aspects including socio-demographic characteristics, COVID-19 infection and vaccine status, awareness of COVID-19 vaccine, motivations, and reasons for vaccine refusal.

Statistical Analysis: Data collected were organized and analysed using MS Excel and SPSS. Percentages were calculated for qualitative variables, while mean and standard deviation (SD) were computed for quantitative variables. Multiple logistic regression analysis was employed to assess the probability of outcomes associated with different variables.

Results:

Statistical analysis was done among 400 participants, and found following results. **Table 1: Sociodemographic characteristics of respondents:**

| Variables (n=400) | Frequency | % | | | | |
|---------------------|-----------|------|--|--|--|--|
| Age in years | | | | | | |
| < 18 | 19 | 4.8 | | | | |
| 18-40 | 251 | 62.7 | | | | |
| 41-60 | 102 | 25.5 | | | | |
| >60 | 28 | 7.0 | | | | |
| Gender | | | | | | |
| Male | 271 | 67.8 | | | | |
| Female | 129 | 32.3 | | | | |
| Area | | | | | | |
| Rural area | 224 | 56.0 | | | | |
| Urban area | 136 | 34.0 | | | | |
| Semi-urban Area | 40 | 10.0 | | | | |
| Education | | | | | | |
| Illiterate | 108 | 27 | | | | |
| Primary education | 27 | 6.8 | | | | |
| Middle school | 30 | 7.5 | | | | |
| High school | 69 | 17.3 | | | | |
| Graduate | 63 | 15.8 | | | | |
| Professional degree | 103 | 25.8 | | | | |
| Marital status | | | | | | |
| Married | 304 | 76.0 | | | | |
| Unmarried | 82 | 20.5 | | | | |
| Other | 14 | 3.5 | | | | |

Scope Volume 14 Number 03 September 2024

Table 1 shows the majority of participants (62.7%, n=251) were from the age group of 18-40 years, followed by (25.5%) 41-60 years. 67.8% (n=271) were male. More than half of the participants (56%, n=226) were from rural areas. Regarding the education level of participants, 41.6% (n=166) of the participants had education graduate and above. Whereas 27% (n=108) of the participants didn't have any formal education.Overall,most of the participants (76%, n=304) are married.

| Does the COVID vaccine protect us from getting infected? | | | | |
|---|-----------------------------|---------------------------|--|--|
| Yes | 384 | 96 | | |
| No | 16 | 4 | | |
| Do you think the COVID v | accination also protects | other people who do not | | |
| get the vaccine? | | | | |
| Yes | 311 | 77.8 | | |
| No | 89 | 22.3 | | |
| Is it necessary to get the CC | VID vaccine even if you h | ave already been infected | | |
| with COVID? | | | | |
| Yes | 399 | 99.8 | | |
| No | 1 | 0.3 | | |
| Do you think vaccines can e | eradicate the COVID pand | emic? | | |
| Yes | 386 | 96.5 | | |
| No | 14 | 3.5 | | |
| Do you think you don't nee | ed a vaccine because you t | ake preventive measures | | |
| seriously? | | | | |
| Yes | 24 | 6.0 | | |
| No | 376 | 94.0 | | |
| Do you think people under | the age of 15 should get th | e COVID vaccine? | | |
| Yes | 360 | 90 | | |
| No | 10 | 2.5 | | |
| Don't know | 30 | 7.5 | | |
| Should people with chronic illness get the COVID vaccination? | | | | |
| Yes | 382 | 95.5 | | |
| No | 18 | 4.5 | | |
| Do you think vaccine should be compulsory for all? | | | | |
| Yes | 399 | 99.8 | | |

Table 2: Awareness regarding COVID-19 vaccine:

| No | 1 | 0.3 |
|----|---|-----|
| | | |

Table 2 is denoting awareness towards COVID-19 vaccination, The vast majority of participants (96%, n=384) were aware that COVID vaccines protect against infection. Additionally, 77.8% (n=311) believed vaccination also safeguards individuals who have not received the vaccine. Almost unanimous agreement (99.8%, n=399) was observed regarding the necessity of COVID vaccination, even for those previously infected. Furthermore, 96.5% (n=386) expressed confidence in the vaccine's potential to eradicate the pandemic. Notably, 94% (n=376) of participants recognized the importance of vaccination despite practicing preventive measures, while 90% and 95.5% advocated for vaccination among individuals under 15 years old and those with chronic illnesses, respectively. The overwhelming majority (99.8%, n=399) perceived vaccination as compulsory for all.

| Factors | Frequency | Percent | | | | |
|---|--|----------------------|--|--|--|--|
| Infected with COVID-19 in the past (| Infected with COVID-19 in the past (n=400) | | | | | |
| Yes | 96 | 24 | | | | |
| No | 297 | 74.3 | | | | |
| Don't know | 7 | 1.8 | | | | |
| Long-term illness among persons wi | th past COVID-19(n= | =96) | | | | |
| Yes | 69 | 71.9 | | | | |
| No | 27 | 28.1 | | | | |
| Type of long-term effects after recov | ering from a COVID | -19 infection (n=69) | | | | |
| Weakness | 36 | 52.2 | | | | |
| Headache | 9 | 13.04 | | | | |
| Body ache | 7 | 10.14 | | | | |
| Anxiety/ Depression | 3 | 4.35 | | | | |
| Breathlessness | 3 | 4.35 | | | | |
| Weakness with other (body ache/ | 7 | 10.14 | | | | |
| breathlessness/ headache) | | | | | | |
| Headache with other (Anxiety/ | 3 | 4.35 | | | | |
| Depression/ Body ache/ | | | | | | |
| Breathlessness) | | | | | | |
| Breathlessness, Anxiety/ Depression | 1 | 1.45 | | | | |
| H/O COVID-19 Infection of Family Member (n=400) | | | | | | |
| Yes | 56 | 14 | | | | |
| No | 344 | 86 | | | | |
| Have you taken COVID-19 vaccination (n=400) | | | | | | |
| Yes | 396 | 99 | | | | |

Table 3: Vaccination status and Determinants of COVID-19 vaccination:

| Ъ.т. | | | | | | |
|--|--|--|--|--|--|--|
| No | 4 | 1 | | | | |
| Doses of COVID-19 vaccine taken by participants (n=396) | | | | | | |
| 1 | 115 | 29 | | | | |
| 2 | 262 | 66.2 | | | | |
| 3 | 19 | 4.8 | | | | |
| Type of COVID-19 vaccine taken by p | articipants (n=396) | | | | | |
| COVAXIN | 79 | 19.9 | | | | |
| COVISHIELD | 255 | 64.4 | | | | |
| Don't know | 62 | 15.7 | | | | |
| The reason behind taking the COVII |) vaccine (n=396) | | | | | |
| For protection | 375 | 94.7 | | | | |
| Other's pressure | 12 | 3.0 | | | | |
| Because it is mandatory in the office | 8 | 2.0 | | | | |
| Other | 1 | 0.3 | | | | |
| Reason behind refusal of COVID-19 v | vaccination(n=4) | | | | | |
| Other (doubt about vaccine and side | 3 | 75 | | | | |
| effects of vaccine) | | | | | | |
| | | | | | | |
| Any contraindication or co-morbidity | 1 | 25 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illne | 1 ess related to CO | 25 OVID infection in | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) | 1 ess related to CO | 25 OVID infection in | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension | 1 ess related to CO 29 | 25 OVID infection in 34.52 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes | 1ess related to CO2918 | 25 OVID infection in 34.52 21.43 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illue Participants(n=84) Hypertension Diabetes Thyroid problem | 1 ess related to CO 29 18 11 | 25 OVID infection in 34.52 21.43 13.10 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary | 1 ess related to CO 29 18 11 7 | 25 OVID infection in 34.52 21.43 13.10 8.33 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) | 1 ess related to C 29 18 11 7 | 25 OVID infection in 34.52 21.43 13.10 8.33 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes | 1 ess related to CO 29 18 11 7 4 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes Obesity | 1 ess related to C 29 18 11 7 4 4 4 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 4.76 4.76 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes Obesity Hypertension with obesity/ Kidney | 1 ess related to CO 29 18 11 7 4 4 4 4 4 4 4 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 4.76 4.76 4.76 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes Obesity Hypertension with obesity/ Kidney disorders /Thyroid problems | 1 ess related to Co 29 18 11 7 4 4 4 4 4 4 4 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 4.76 4.76 4.76 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes Obesity Hypertension with obesity/ Kidney disorders /Thyroid problems Liver diseases and Obesity/ Thyroid | 1 ess related to Co 29 18 11 7 4 4 4 4 4 4 4 4 4 4 4 4 4 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 4.76 4.76 4.76 4.76 4.76 4.76 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes Obesity Hypertension with obesity/ Kidney disorders /Thyroid problems Liver diseases and Obesity/ Thyroid problem | 1 ess related to CO 29 18 11 7 4 4 4 4 4 4 4 4 4 4 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 4.76 4.76 4.76 4.76 4.76 4.76 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illne Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes Obesity Hypertension with obesity/ Kidney disorders /Thyroid problems Liver diseases and Obesity/ Thyroid problem Diabetes and others | 1 ess related to Co 29 18 11 7 4 4 4 4 4 4 2 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 4.76 4.76 4.76 2.38 | | | | |
| Any contraindication or co-morbidity Different types of Chronic illno Participants(n=84) Hypertension Diabetes Thyroid problem Others (COPD/ asthma, pulmonary tuberculosis/ malignancy) Hypertension and Diabetes Obesity Hypertension with obesity/ Kidney disorders /Thyroid problems Liver diseases and Obesity/ Thyroid problem Diabetes and others Thyroid problems and obesity | 1 ess related to Co 29 18 11 7 4 4 4 4 4 4 4 1 2 1 | 25 OVID infection in 34.52 21.43 13.10 8.33 4.76 4.76 4.76 4.76 4.76 2.38 1.19 | | | | |

Table 3 regarding the COVID infection and vaccination status of participants, only 24% (n=96) of participants had a history of COVID-19 infection as of February 2022. Among those infected, approximately 72% (n=69) reported experiencing long-term illness, with weakness (52.2%) being the most common symptom, followed by headache (13.4%), body aches (10.14%), anxiety/depression (4.35%), and breathlessness

(4.35%).The majority of participants did not have any family members with a history of COVID-19 infection.Regarding vaccination status, nearly all participants (99%, n=396) were either partially (29%) or fully (66.2%) vacci/nated, with Covishield being the most commonly received vaccine (64.4%, n=255). The primary reason for vaccination was self-protection (94.7%, n=375).

Regarding comorbidities, approximately 21% (n=84) of participants reported having chronic illnesses or comorbidities, with hypertension (4.5%, n=29) being the most prevalent, followed by diabetes (21.4%, n=18), thyroid problems (13%, n=11), and COPD/Asthma/PTB/Malignancy (8.33%, n=7). Notably, hypertension combined with other comorbidities was the most common combination.

| | Frequency (n=396) | Percent | | | |
|---|---------------------|---------|--|--|--|
| The motivation behind the vaccination of participants | | | | | |
| Self | 289 | 73.0 | | | |
| Health personnel | 39 | 9.8 | | | |
| Media | 25 | 6.3 | | | |
| Family members | 23 | 5.8 | | | |
| Institution as the compulsory norm | 12 | 3.0 | | | |
| Friend | 3 | 0.8 | | | |
| Other | 3 | 0.8 | | | |
| Colleagues | 2 | 0.5 | | | |
| Total | 396 | 100.0 | | | |
| Has motivated others to vaccinate? | | | | | |
| Yes | 327 | 82.6 | | | |
| No | 69 | 17.4 | | | |
| The time gap between motivation and getti | ng COVID-19 Vaccina | ation | | | |
| < 1 month | 209 | 52.8 | | | |
| 1- 3 month | 140 | 35.4 | | | |
| > 3 months | 47 | 11.9 | | | |
| Reason for delay in taking COVID vaccine | | | | | |
| None | 325 | 82.1 | | | |
| Fear of vaccine-related adverse effects | 26 | 6.6 | | | |
| Less availability of vaccine | 13 | 3.3 | | | |
| The vaccination center was located far away | 13 | 3.3 | | | |
| Other Reason | 10 | 2.5 | | | |
| Doubt about the safety of vaccine | 7 | 1.8 | | | |
| Doubt about the effectiveness of vaccine | 2 | 0.5 | | | |
| Regret about taking COVID vaccination | | | | | |
| Yes | 126 | 31.8 | | | |

Table 4: Factors associated with vaccination of participants:

Scope Volume 14 Number 03 September 2024

| No | 270 | 68.2 | | |
|--|-----|------|--|--|
| Observed any adverse event after COVID vaccination | | | | |
| Yes | 107 | 27.0 | | |
| No | 289 | 73.0 | | |
| Adverse events after Vaccination (n=107) | | | | |
| Fever | 46 | 43.0 | | |
| Anxiety | 25 | 23.4 | | |
| Rash | 14 | 13.1 | | |
| Chills | 12 | 11.2 | | |
| Localized pain | 6 | 5.6 | | |
| Nausea/ Vomiting | 3 | 2.8 | | |
| Others | 1 | 0.9 | | |

Table 4 shows approximately three-fourths of participants (73.0%, n=289) were selfmotivated to receive the COVID vaccination.

- Among these, a significant proportion (82.6%, n=327) encouraged others to get vaccinated, and more than half (52.8%, n=208) received their vaccination within a month.

- The majority (82%, n=325) did not cite any reason for delaying vaccination, while reasons for delay included fear of adverse effects (6.6%, n=26), limited vaccine availability (3.3%, n=13), and distance to vaccination centers (3.3%, n=13).

- A substantial number of participants (31.8%, n=126) expressed regret after vaccination.

- Among vaccinated individuals, 27% (n=107) reported experiencing some form of adverse event, with fever (43%, n=46) and anxiety (23.4%, n=25) being the most common.

The multivariate logistic regression model adjusted for various confounders, including age category, past COVID infection, presence of chronic illness, past COVID infection among family members, motivation for vaccination, and observation of adverse events post-vaccination. Predictors with p-values less than 0.1 in the bivariate analysis were included in the multivariate analysis.

| Variables | Category | Fully | Partial | p-value | OR | Adjust | Adjuste |
|-----------|------------|-------------|------------|------------|--------|---------|---------|
| | | vaccinate | vaccinat | (Chi- | 95% | ed OR | d p- |
| | | d | ed | square) | CI | 95% CI | value |
| | | 281 (71%) | 115 (29%) | | | | |
| Age | 41-60, >60 | 102 (78.5%) | 28(21.5%) | 1.85 | 0.013* | 2.34 | 0.003* |
| category | <18,18-40 | 179 (66.3%) | 91 (33.7%) | (1.14 - | (6.214 | (1.34- | |
| | years | | | 3.02) |) | 4.07) | |
| Past | No, Don't | 222 (73.0%) | 82 | 1.70 (1.05 | 0.031* | 1.18 | 0 .564 |
| COVID | know | | (27.0%) | - 2.75) | (4.67 | (0.67 - | |
| infection | Yes | 59 (61.5%) | 37 | | 2) | 2.05 | |
| | | | (38.5%) | | | | |
| Presence | Yes | 52 (61.9%) | 32 (38.1%) | 0.62 | 0.060 | 0.61 | 0.113 |
| of | No | 229 | 87 | (0.37 - | (3.543 | (0.33- | |
| chronic | | (72.5%) | (27.5%) | 1.02) |) | 1.12) | |
| illness | | | | | | | |
| Past | No, don't | 252 (73.3%) | 92 | 2.55 | 0.001* | 2.10 | 0.023* |
| COVID | know | | (26.7%) | (1.43 - | (10.62 | (1.11- | |
| infection | Yes | 29 (51.8%) | 27 | 4.54) | 2) | 3.97) | |
| of family | | | (48.2%) | | | | |
| member | | | | | | | |
| S | | | (| | | | |
| Motivati | Family, | 94 (87.9%) | 13 (12.1%) | 3.94 | <0.00 | 3.21 | <0.001* |
| on to | Friends, | | | (2.10 - | 1* | (1.68 - | |
| vaccinat | Health | | | 7.39) | (20.2 | 6.14) | |
| e | care | | | | 99) | | |
| | personnel, | | | | | | |
| | Others | | | | | | |
| | Self | 187 (64.7%) | 102(35.3% | | | | |
| | | |) | | | | |

Table 5: The multivariate logistic regression model for vaccination status of participants and different confounders:

After adjusting for confounders, age, past COVID infection of family members, and motivation to vaccinate showed significant associations with vaccination status, with p-values of 0.003, 0.023, and <0.001, respectively. Individuals aged 41-60 and those over 60 years had 2.34 times higher odds of being fully vaccinated (95% CI= 1.34-4.07) compared to those aged under 18 or between 18-40 years. Participants without any family members who had experienced past COVID infection had 2.10 times higher odds of being fully vaccinated (95% CI= 1.11-3.97) compared to those with affected family members. Furthermore, individuals motivated by family, friends, healthcare personnel, or others

had 3.21 times higher odds of being fully vaccinated (95% CI= 1.68 -6.14) compared to those who were self-motivated. (**Table 5**)

| | | Vaccination status | | Odd's ratio | P-value and |
|-----------|-------------|----------------------|-----------------|--------------|-------------|
| | | | | with 95% | Chi-square |
| | | | | CI | |
| | | Fully vaccinated | Partially or | | |
| | | 281 (70.3%) | not | | |
| | | | vaccinated 119 | | |
| | | | (29.8%) | | |
| Gender | Male | 187 (69.0%) | 84 (31.0%) | 0.83 (0.52 - | 0.429 |
| | Female | 94 (72.9%) | 35 (27.1%) | 1.32) | (0.625) |
| Educatio | Graduate | 109 (65.7%) | 57 (34.3%) | 0.84 (0.50- | 0.109 |
| nal | and above | | | 1.41) | (4.439) |
| category | | | | | |
| | Primary to | 97 (77.0%) | 29 (23.0%) | 1.47 (0.82 - | |
| | high school | | | 2.64) | |
| | Illiterate | 75 (69.4%) | 33 (30.6%) | Reference | |
| | | Does vaccination als | o protect other | | |
| | | people who do not g | et the vaccine? | | |
| | | No | Yes | | |
| Vaccinati | Fully | 81 (28.8%) | 200 (71.2%) | 5.62 (2.62 - | <0.001* |
| on of | vaccinated | | | 12.05) | (23.608) |
| status | Partial | 8 (6.7%) | 111 (93.3%) | | |
| | vaccinated | | | | |
| Total | | 89 (22.3%) | 311 (77.8%) | | |

Table 6: Association of gender, educational status vs. Vaccination status:

Table 6shows a higher proportion of females (72.9%, n=94) were fully vaccinated compared to males (69%), although no significant association was found between gender and vaccination status.

Participants who had completed primary, middle, or higher school (77.0%, n=97) exhibited a higher rate of full vaccination compared to those with graduate and professional degrees (65.7%, n=109) and individuals with no formal education (69.4%, n=75). However, there was no significant association between educational status and vaccination status.

A highly significant association was observed between COVID vaccination status and the perception of vaccination providing protection to unvaccinated individuals (p-value < 0.001). Fully vaccinated individuals were 5.62 times more likely to perceive that

vaccination does not protect unvaccinated people (95% CI = 2.62-12.05) compared to those who believed that vaccination provides protection to non-recipients.

There is a highly significant association between the presence of chronic illness and past COVID infection, with a p-value of <0.001 and odds ratio of 4.85 (95% CI= 2.89- 8.15).

| Table 7: Association of the presence of chronic illness with past-COVID infection |
|---|
| and motivation to vaccine with motivating others to vaccinate: |

| | | Past COVID | infection | Odd's ratio | P-value and |
|--------------|---|-------------------------|--------------------|--------------|-------------|
| | | V V D | | with 95% CI | Chi-square |
| | | Yes | No, Do not know | | |
| Presence of | Yes | 42 (50.0%) | 42 (50.0%) | 4.85 | <0.001* |
| illness | No | 54 (17.1%) | 262 (82.9%) | (2.89- 8.15) | (39.407) |
| Total | | 96 (24.0%) | 304 (76.0%) | | |
| | | Motivating vaccinate | others to | | |
| | | Yes | No | | |
| Motivation | Self | 266 (92.0%) | 23 (8.0%) | 8.72 (4.92 - | <0.001* |
| to vaccinate | Friends, family, health care personn el, and others | 61 (57.0%) | 46 (43%) | 15.46) | (66.606) |
| Total | 1 | 327 (82.6%) | 69 (17.4%) | | |

Additionally, there is a highly significant association between individuals being motivated and motivating others for vaccination, with a p-value of <0.001. Individuals who were self-motivated for vaccination had 8.72 times higher odds of motivating others to vaccinate (95% CI= 4.92- 15.46) compared to those motivated by friends, family, health care personnel, or others. (**Table 7**)

Discussion: The success of any COVID-19 vaccination campaign hinges upon widespread acceptance among the general population. Our questionnaire was instrumental in gauging vaccine acceptance and assessing knowledge and attitudes surrounding the COVID-19 vaccine. We included a total of 400 respondents in our study, with 62.7% falling within the 18-40 age bracket. The gender distribution showed that 67.8% were male and 32.3% were female, while 56% hailed from rural areas. A majority (58.9%) of participants had received education up to high school level or above. These demographics differ from findings in other regions. For instance, a study in Jammu & Kashmir ⁸ reported 69.6% male and 30.4% female participants, with a mean age of 34.2 \pm 11.2 years. Furthermore, 68.5% of participants were from urban areas, contrasting with our predominantly rural sample. Similar result found in the study of AlrefaeiAf et al, Saudi Arabia, there were 73.5% male. More than half of respondents were 18–28 (65%), and 95.8% had education at high school and higher.⁹

Our study revealed that 96% of participants were aware of the protective role of COVID-19 vaccines against infection, and a similar percentage believed in its potential to eradicate the pandemic. Additionally, 90% and 95.5% of respondents endorsed vaccination for individuals under 15 years of age and those with chronic illnesses, respectively. Notably, 99.8% of participants felt that vaccination should be mandatory for all. This contrasts with findings by Subramani et al. ³, where only 38% believed in the preventive efficacy of the COVID-19 vaccine, and 27% people believe that COVID-19 vaccine will provide complete protection against COVID-19 disease. Another study states that the awareness regarding COVID-19 and its vaccination was about 74% among the study population.⁸

Motives for vaccination varied across studies. While Štěpánek et al.^[10] found family protection to be the primary motive (76.2%) and 49.1% for self-concern, whereas our study indicated that 94.7% of respondents were vaccinated for self-protection.

Post-vaccination adverse effect was reported by 27% of vaccinated participants, with fever (43%) and anxiety (23.4%) being the most prevalent in present study. This differs slightly from finding of central India study, where 29.8% reported adverse events, with pain at the injection site (14.6%), fever (9.7%), and myalgia (5.9%) being commonly reported.¹¹

A notable proportion (75%) of respondents had doubts about the vaccine and feared its side effects, while 25% reported chronic illness as a reason for vaccine refusal. These findings echo those of Cerda and García,¹² who identified concerns about vaccine side effects and risk perception as primary reasons for vaccine hesitancy.

In conclusion, our study sheds light on the nuanced factors influencing COVID-19 vaccine acceptance and hesitancy in Madhya Pradesh, India. These insights are vital for tailoring vaccination strategies and addressing public concerns, ultimately enhancing vaccine uptake and mitigating the impact of the ongoing pandemic.

Factors Associated with Participants' COVID-19 Vaccination Status:

In our study, after adjusting for potential confounding factors through multivariable logistic regression analysis, several variables emerged as significantly associated with vaccination status (p < 0.05). Specifically, age, family history of COVID-19 infection, and sources of motivation for vaccination showed significant associations.

- Age Categories: Participants aged 41-60 and those above 60 years exhibited 2.34 times higher odds of being fully vaccinated (95% CI= 1.34-4.07) compared to individuals below 18 and those between 18-40 years old.
- Family History of COVID-19 Infection: Individuals without any family members infected with COVID-19 in the past demonstrated 2.10 times higher odds of being fully vaccinated (95% CI= 1.11-3.97) compared to those with affected family members.
- Sources of Motivation for Vaccination: Participants motivated by family, friends, healthcare personnel, or other sources showed 3.21 times higher odds of being fully vaccinated (95% CI= 1.68 -6.14) compared to those who were self-motivated.

Additional Observations:

- Gender Disparity: A higher proportion of females (72.9%) were fully vaccinated compared to males (69%).
- Educational Attainment: Interestingly, a higher proportion (77.0%) of individuals who had completed primary, middle, or higher school were fully vaccinated compared to those with graduate and professional degrees (65.7%) and individuals with no formal education (69.4%). However, no significant association was found between educational status and vaccination status.

Conclusion:

This study delved into various population characteristics to glean insights essential for effective vaccination awareness campaigns aimed at combating COVID-19 transmission. While appreciable awareness levels regarding the COVID-19 vaccination was observed amongst the study population, sustained efforts are imperative to further educate the populace on the safety, efficacy, and benefits of vaccination.

Policymakers can utilise diversified methods in disseminating information regarding pandemic appropriate behaviour and vaccination through various channels, including social media platforms and mass communication methods. Additionally, the establishment of specialized media cells is recommended to combat the proliferation of rumours, myths, and misinformation, which pose significant obstacles to vaccination efforts. Vigilance in this regard is crucial as the threat of infection resurgence remains ever-present.

By prioritizing robust vaccination awareness initiatives and leveraging effective communication strategies, we can empower individuals to make informed decisions regarding vaccination, thereby support public health resilience against any pandemic similar to the COVID-19 and other future health threats.

Acknowledgment: We would like to acknowledge the support from higher state officials, Additional Chief Secretary Health Commissioner Health, and Director of Health and District IDSP team Bhopal.

Funding: none Conflict of interest: None

Author Address:

¹MBBS, MD, Community Medicine, Senior Resident, Community and Family Medicine, AIIMS, Bhopal (Current), PGMO in Directorate of Health services, Bhopal (where present study was done)

²MBBS, MD, Community Medicine, Assistant Professor, Peoples College of medical science and research centre, Bhopal

³MBBS, MS, ENT, Deputy Director, IDSP, Directorate of Health services, Bhopal ⁴MBBS, MD, MPH, Ex-Commissioner Health, Principal Revenue Commissioner office, Vallabh Bhavan

⁵MBBS, MD, Additional Director, IDSP, Directorate of Health services, Bhopal ⁶M.Sc.(Zoology), State Entomologist, IDSP, Directorate of Health services, Bhopal ⁷B.Tech (CSE), State data manager, IDSP, Directorate of Health services, Bhopal

References:

- Andrews M, Areekal B, Rajesh K, Krishnan J, Suryakala R, Krishnan B, et al. (2020) First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res, 151(5):490.
- Subramani P, James J, Saikia K. (2022) Awareness on COVID 19 vaccination among public: a questionnaire surveys. Int J Community Med Public Health. (1):288-293.
- Rouf A, Nazir F, Masoodi MA. (2021) Awareness, attitude and practice of COVID-19 and its vaccination in J&K, India. Indian J Forensic Community Med, 8(4):220–6.
- Alrefaei AF. (2022) Assessment of health awareness and knowledge toward SARS-CoV-2 and COVID-19 vaccines among residents of Makkah, Saudi Arabia.Clinical Epidemiology and Global Health.
- Štěpánek L, Janošíková M, Nakládalová M, Ivanová K, Macík J, Boriková A, et al. (2021) Motivation for COVID-19 Vaccination in Priority Occupational Groups: A Cross-Sectional Survey. Int J Environ Res Public Health,18(21):11726.

- Swayam Pragyan Paridai, Dinesh Prasad Sahui, Arvind Kumar Singhi, G. Alekhyai, SonuHangma Subbai, Abhisek Mishrai, Biswa Mohan Padhy, Binod Kumar Patroi. (2022) Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol, 94(6):2453-2459.
- Cerda AA, García LY. (2021) Hesitation and Refusal Factors in Individuals' Decision-Making Processes Regarding a Coronavirus Disease 2019 Vaccination. Front Public Health.